Discovery of the Next-Generation Platinum-Based Anticancer Agents for Combating Oxaliplatin-Induced Drug Resistance-Reference-Cited by-同舟云学术

Discovery of the Next-Generation Platinum-Based Anticancer Agents for Combating Oxaliplatin-Induced Drug Resistance

Published:2024-06-07 Issue:12 Volume:67 Page:10190-10210
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sun Ziru¹,Han Jianbin²,Xu Jun¹^ORCID,Song Weijie¹³,Cui Yujun¹⁴,Liu Yang²,Yang Liu²,Meng Xiaoqi¹,Huang Jie¹,Gao Qingzhi¹^ORCID,Liu Shengnan¹²

Affiliation:

1. School of Pharmaceutical Science and Technology, Institute of Molecular Plus, Frontiers Science Center for Synthetic Biology (Ministry of Education of China), Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, Tianjin University, 92 Weijin Road, Nankai District, Tianjin 300072, P. R. China

2. Department of Biology, Tianjin Key Laboratory of Innovative Drugs Targeting the Central Nervous System, Gudui BioPharma Technology Inc., 5 Lanyuan Road, Huayuan Industrial Park, Tianjin 300384, P. R. China

3. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, West Huanhu Road, Hexi District, Tianjin 300060, P. R. China

4. Transplantation Center, Tianjin First Central Hospital, 24 Fukang Road, Nankai District, Tianjin 300192, P. R. China

Funder

Tianjin University

National Natural Science Foundation of China

Gudui BioPharma Technology Inc.

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00366

Reference52 articles.

1. Review article: obesity and colorectal cancer

2. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy

3. 5-Fluorouracil Administered as a 48-Hour Chronomodulated Infusion in Combination with Leucovorin and Cisplatin: A Randomized Phase II Study in Metastatic Colorectal Cancer

4. Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy

5. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines